 Opiant Pharmaceuticals Inc NASDAQ: OPNT has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder AUD. The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization WHO drinking risk levels. 